Drugs / PfSPZ Vaccine
PfSPZ Vaccine
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 116 trials | ||||||
| Phase 1 | NCT05652504 | Jul → Nov 2026 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Suspended | No outcome recorded |
| Phase 1 | NCT04966871 | Sep 2021 → Jun 2022 | Plasmodium falciparum malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03590340 | Jul 2018 → Mar 2019 | malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03510481 | May 2018 → Nov 2019 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03420053 | Feb → Aug 2018 | Plasmodium falciparum malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03163121 | May 2017 → Oct 2018 | malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02859350 | Nov 2016 → Dec 2017 | malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02663700 | Apr 2016 → Dec 2018 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02627456 | Dec 2015 → Mar 2018 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02613520 | Dec 2015 → Feb 2017 | malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02418962 | Mar → Sep 2015 | Plasmodium falciparum malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02215707 | Jun 2014 → Apr 2015 | malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02132299 | Apr 2014 → Jul 2015 | Plasmodium falciparum malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02015091 | Dec 2013 → May 2015 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01988636 | Oct 2013 → Aug 2015 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01001650 | Apr 2009 → Jul 2010 | Plasmodium falciparum malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02687373 | Jul 2016 → Aug 2018 | malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03503058 | May 2022 → Feb 2024 | malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03989102 | Jul 2019 → Apr 2022 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT03521973 | Jun 2018 → May 2021 | malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02601716 | Jan 2016 → Sep 2017 | malaria | Sanaria Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05604521 Comparator | Dec 2022 → Sep 2023 | Plasmodium falciparum malaria | Sanaria Inc. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PfSPZ vaccine | “Dose Escalation Study of Sanaria's Irradiated Sporozoite Vaccine (PFSPZ Vaccine), Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial” NCT02663700 ↗22“Clinical Trial of the PfSPZ Vaccine” NCT01001650 ↗ |
| Known as | PfSPZ | “PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.” NCT02663700 ↗ |
| Known as | Plasmodium falciparum sporozoite Vaccine | “Sanaria® PfSPZ Vaccine (Plasmodium falciparum sporozoite Vaccine) is being developed for this purpose.” PMID 29141739 ↗ Jan 2018 |
| Known as | Sanaria PfSPZ Vaccine | “USSPZV7 is a randomized, phase 1, double-blind, placebo-controlled trial of Sanaria® PfSPZ Vaccine administered on Days 1, 8 and 29 by direct venous inoculation (DVI) to assess...” NCT05604521 ↗2“Sanaria PfSPZ Vaccine, composed of attenuated Plasmodium falciparum (Pf) sporozoites (SPZ), protects against malaria.” PMID 38194272 ↗ Jan 2024 “Sanaria® PfSPZ Vaccine (Plasmodium falciparum sporozoite Vaccine) is being developed for this purpose.” PMID 29141739 ↗ Jan 2018 |
| Modality | Vaccine | “a non-replicating, metabolically active Plasmodium falciparum sporozoite (PfSPZ) vaccine” NCT01001650 ↗ |
| Route | Subcutaneous | “PfSPZ Vaccine Administered Subcutaneously or Intradermally” NCT01001650 ↗ |